7L7B
Clostridioides difficile RNAP with fidaxomicin
7L7B の概要
| エントリーDOI | 10.2210/pdb7l7b/pdb |
| EMDBエントリー | 23210 |
| 分子名称 | DNA-directed RNA polymerase subunit alpha, DNA-directed RNA polymerase subunit beta, DNA-directed RNA polymerase subunit beta', ... (9 entities in total) |
| 機能のキーワード | fidaxomicin, clostridioides difficile rna polymerase, transcription, transcription-inhibitor complex, transcription/inhibitor |
| 由来する生物種 | Clostridia bacterium 詳細 |
| タンパク質・核酸の鎖数 | 6 |
| 化学式量合計 | 398105.85 |
| 構造登録者 | Boyaci, H.,Campbell, E.A.,Darst, S.A.,Chen, J. (登録日: 2020-12-28, 公開日: 2022-02-02, 最終更新日: 2025-05-21) |
| 主引用文献 | Cao, X.,Boyaci, H.,Chen, J.,Bao, Y.,Landick, R.,Campbell, E.A. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature, 604:541-545, 2022 Cited by PubMed Abstract: Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains unknown. Cdiff infections are a leading cause of nosocomial deaths. Fidaxomicin, which inhibits RNA polymerase, targets Cdiff with minimal effects on gut commensals, reducing recurrence of Cdiff infection. Here we present the cryo-electron microscopy structure of Cdiff RNA polymerase in complex with fidaxomicin and identify a crucial fidaxomicin-binding determinant of Cdiff RNA polymerase that is absent in most gut microbiota such as Proteobacteria and Bacteroidetes. By combining structural, biochemical, genetic and bioinformatic analyses, we establish that a single residue in Cdiff RNA polymerase is a sensitizing element for fidaxomicin narrow-spectrum activity. Our results provide a blueprint for targeted drug design against an important human pathogen. PubMed: 35388215DOI: 10.1038/s41586-022-04545-z 主引用文献が同じPDBエントリー |
| 実験手法 | ELECTRON MICROSCOPY (3.26 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






